Abstract
Conventionally, the recommended duration of adjuvant chemotherapy had been 6 months. The recent combined analysis by the IDEA Collaboration for stage III colon cancer suggested that shortening the oxaliplatin-based adjuvant chemotherapy may be possible. Especially, in the IDEA low-risk stage III, 3 months of CAPOX was shown to be non-inferior to 6 months. S-1 and oxaliplatin treatment (SOX) + bevacizumab was shown to be non-inferior to FOLFOX + bevacizumab as first-line chemotherapy in metastatic colorectal cancer patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have